Sirolimus-Based Immunosuppression Therapy in Liver Transplantation for Patients With Hepatocellular Carcinoma Exceeding the Milan Criteria

Transplantation Proceedings

Volumn 40, Issue 10, 2008, Pages 3548-3553

  Zhou, J ^a   Wang, Z ^a   Wu, Z Q ^a   Qiu, S J ^a   Yu, Y ^a   Huang, X W ^a   Tang, Z Y ^a   Fan, J ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IRON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ARTERY THROMBOSIS; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IRON THERAPY; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MOUTH ULCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PATIENT SELECTION; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS; SURVIVORS; TACROLIMUS;

EID: 57549102087     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.165     Document Type: Article

References (25)

1. Parkin D.M., Bray F., and Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74
2. Yu A.S., and Keeffe E.B. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 3 (2003) 8
3. Mazzaferro V., Regalia E., and Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693
4. Cillo U., Vitale A., and Bassanello M. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 239 (2004) 150
5. Majumder P.K., Febbo P.G., and Bikoff R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594
6. Carraway H., and Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6 (2004) 219
7. Panwalkar A., Verstovsek S., and Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100 (2004) 657
8. Starzl T.E., Iwatsuki S., and Esquivel C.O. Refinements in the surgical technique of liver transplantation. Semin Liver Dis 5 (1998) 349
9. Takada Y., Ueda M., and Ito T. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 12 (2006) 912
10. Onaca N., Davis G.L., and Goldstein R.M. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 13 (2007) 391
11. Duffy J.P., Vardanian A., and Benjamin E. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 246 (2007) 502
12. Tanaka K. Progress and future in living donor liver transplantation. Keio J Med 52 (2003) 73
13. Moray G., Karakayali F., and Yilmaz U. Expanded criteria for hepatocellular carcinoma and liver transplantation. Transplant Proc 39 (2007) 1171
14. Freise C.E., Ferrell L., and Liu T. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 67 (1999) 510
15. Hojo M., Morimoto T., and Maluccio M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530
16. Vivarelli M., Cucchetti A., and Piscaglia F. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 11 (2005) 497
17. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680
18. Schumacher G., Oidtmann M., and Rosewicz S. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 34 (2002) 1392
19. Guba M., von B.P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128
20. Luan F.L., Ruchuang D., and Sharma V.K. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63 (2003) 917
21. Luan F.L., Hojo M., and Maluccio M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73 (2002) 1565
22. Kneteman N.M., Oberholzer J., and Al Saghier M. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Live Transpl 10 (2004) 1301
23. Stippel D.L., Kasper H.U., and Schleimer K. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 37 (2005) 2185
24. Elsharkawi M., Staib L., and Henne-Bruns D. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 79 (2005) 854
25. Zhou J., Fan J., and Wang Z. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J Gastroenterol 12 (2006) 3114